Emergency versus elective living-donor liver transplantation: A comparison of a single center analysis

Surgery Today

Volumn 42, Issue 5, 2012, Pages 453-459

  Takeda, Kazuhisa ^a   Tanaka, Kuniya ^a   Kumamoto, Takafumi ^a   Nojiri, Kazunori ^a   Mori, Ryutaro ^a   Taniguchi, Koichi ^a   Matsuyama, Ryusei ^a   Endo, Itaru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Emergency living donor liver transplantation; Invasive pulmonary aspergillosis; Postoperative pneumonia

Indexed keywords

BETA 1,3 GLUCAN; COTRIMOXAZOLE; FLOMOXEF; GABEXATE MESILATE; METHYLPREDNISOLONE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFAMSTAT MESILATE; OXYGEN; PROSTAGLANDIN E1; STEROID; TACROLIMUS;

ACUTE ON CHRONIC LIVER FAILURE; ADULT; AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTERIAL OXYGEN TENSION; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; ELECTIVE SURGERY; EMERGENCY SURGERY; END STAGE LIVER DISEASE; ENDOTRACHEAL INTUBATION; FEMALE; HEMODIAFILTRATION; HEPATIC ENCEPHALOPATHY; HUMAN; KIDNEY DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; LIVING DONOR LIVER TRANSPLANTATION; LUNG ALVEOLUS OXYGEN TENSION; LUNG ASPERGILLOSIS; LYMPHOCYTE COUNT; MALE; PEROPERATIVE CARE; PNEUMOCYSTOSIS; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; RISK FACTOR; RISK REDUCTION; STEROID THERAPY; SURGICAL MORTALITY; TREATMENT DURATION; TREATMENT INDICATION;

ADULT; CAUSALITY; CAUSE OF DEATH; COMORBIDITY; EMERGENCY TREATMENT; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITAL MORTALITY; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PNEUMONIA; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PULMONARY ASPERGILLOSIS; RISK FACTORS; ROC CURVE; SURGICAL PROCEDURES, ELECTIVE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84863496035     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-0040-5     Document Type: Article

References (29)

1. Hong SK, Hwang S, Lee SG, Lee LS, Ahn CS, Kim KH, et al. Pulmonary complications following adult liver transplantation. Transplant Proc. 2006;38:2979-81.
2. Yoshimura N, Okajima H, Ushigome H, Sakamoto S, Fujiki M, Okamoto M. Current status of organ transplantation in Japan and worldwide. Surg Today. 2010;40:514-25.
3. Campsen J, Blei AT, Emond JC, Everhart JE, Freise CE, Lok AS, et al. Adult-to-Adult Living Donor Liver Transplantation Cohort Study Group. Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study. Liver Transpl. 2008;14:1273-80.
4. Matsui Y, Sugawara Y, Yamashiki N, Kaneko J, Tamura S, Togashi J, et al. Living donor liver transplantation for fulminant hepatic failure. Hepatol Res. 2008;38:987-96.
5. Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, Lai CL, et al. Live donor liver transplantation for fulminant hepatic failure in children. Liver Transpl. 2003;9:1185-90.
6. Liu CL, Fan ST, Lo CM, Yong BH, Fung AS, Wong J. Right-lobe live donor liver transplantation improves survival of patients with acute liver failure. Br J Surg. 2002;89:317-22.
7. Liu CL, Fan ST, Lo CM, Wei WI, Yong BH, Lai CL, et al. Livedonor liver transplantation for acute-on-chronic hepatitis B liver failure. Transplantation. 2003;76:1174-9.
8. Uemoto S, Inomata Y, Sakurai T, Egawa H, Fujita S, Kiuchi T, et al. Living donor liver transplantation for fulminant hepatic failure. Transplantation. 2000;70:152-7.
9. Nishizaki T, Hiroshige S, Ikegami T, Uchiyama H, Hashimoto K, Soejima Y, et al. Living-donor liver transplantation for fulminant hepatic failure in adult patients with a left-lobe graft. Surgery (St. Louis). 2002;131:S182-9.
10. Cariús LP, Pacheco-Moreira LF, Balbi E, Leal CR, Gonzalez AC, Agoglia LV, et al. Living donor liver transplantation for acute liver failure: a single center experience. Transplant Proc. 2009; 41:895-7.
11. Escorsell Mañosa A, Mas Ordeig A. Acute on chronic liver failure. Gastroenterol Hepatol. 2010;33:126-34.
12. Yokoi T, Oda S, Shiga H, Matsuda K, Sadahiro T, Nakamura M, et al. Efficacy of high-flow dialysate continuous hemodiafiltration in the treatment of fulminant hepatic failure. Transfus Apher Sci. 2009;40:61-70.
13. Sekido H, Matsuo K, Takeda K, Ueda M, Morioka D, Kubota T, et al. Usefulness of artificial liver support for pretransplant patients with fulminant hepatic failure. Transplant Proc. 2004;36: 2355-6.
14. Takeda K, Morioka D, Kumamoto T, Matsuo K, Tanaka K, Endo I, et al. A survival case of ABO-incompatible liver transplantation complicated with severe preoperative infection and subsequent overwhelming postsplenectomy infection. Transplant Proc. 2009;41:3941-4.
15. Takeda K, Tanaka K, Morioka D, Kumamoto T, Endo I, Togo S, et al. Pathogenesis in ABO incompatible liver transplantation: a clinicohistological evaluation of four patients. Clin Transpl. 2010;24:747-51.
16. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
17. Takeda K, Morioka D, Matsuo K, Endo I, Sekido H, Moroboshi T, et al. A case of successful resection after long-term medical treatment of invasive pulmonary aspergillosis following living donor liver transplantation. Transpl Proc. 2007;39:3505-8.
18. Collins LA, Samore MH, Roberts MS, Luzzati R, Jenkins RL, Lewis WD, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994;170:644-52.
19. Fortún J, Martín-Dávila P, Moreno S, De Vicente E, Nuño J, Candelas A, et al. Liver risk factors for invasive aspergillosis in liver transplant recipients. Transplantation. 2002;8:1065-70.
20. Shi-Chun L, Meng-Long W, Ning L, Wei L, Ping C, Jin-Ning L, et al. Emergent right lobe adult-to-adult living-donor liver transplantation for high model for end-stage liver disease score severe hepatitis. Transpl Int. 2010;23:23-30.
21. Osawa M, Ito Y, Hirai T, Isozumi R, Takakura S, Fujimoto Y, et al. Risk factors for invasive aspergillosis in living donor liver transplant recipients. Liver Transpl. 2007;13:566-70.
22. Rosenhagen M, Feldhues R, Schmidt J, Hoppe-Tichy T, Geiss HK. A risk profile for invasive aspergillosis in liver transplant recipients. Infection. 2009;37:313-9.
23. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2008;61:411-6.
24. Hayette MP, Vaira D, Susin F, Boland P, Christiaens G, Melin P, et al. Detection of Aspergillus species DNA by PCR in bronchoalveolar lavage fluid. J Clin Microbiol. 2001;39:2338-40.
25. Iwama A, Yoshida M, Miwa A, Obayashi T, Sakamoto S, Miura Y. Improved survival from fungaemia in patients with haematological malignancies: analysis of risk factors for death and usefulness of early antifungal therapy. Eur J Haematol. 1993;51: 156-60.
26. Cakman I, Rohwer J, Schütz RM, Kirchner H, Rink L. Dysregulation between TH1 and TH2 T cell subpopulations in the elderly. Mech Ageing Dev. 1996;87:197-209.
27. Mandell MS. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era. Liver Transpl. 2004;10:S54-8.
28. Martin T, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2010; 12:45-50.
29. Figueiredo F, Dickson ER, Pasha T, Kasparova P, Therneau T, Malinchoc M, et al. Impact of nutritional status on outcomes after liver transplantation. Transplantation. 2000;70:1347-52.